Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography–computed tomography: normal patterns, pearls, and pitfalls

Foley, R.; Redman, Stewart; Graham, Richard; Loughborough, Will; Little, David

doi:10.1016/j.crad.2020.06.031

Cited by 28 publications

(19 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After successful preclinical studies [14], 18 F-PSMA-1007 has been introduced in clinical practice. is biodistribution of this PET radiopharmaceutical is similar compared to other PSMA-targeted agents [13][14][15][16]. e increased uptake of this radiopharmaceutical in PCa lesions compared with other PSMA-targeted tracers improves tumor-to-background ratios, facilitating the detection of small PCa lesions.…”

Section: Introductionmentioning

confidence: 73%

“…Currently, 68 Ga-PSMAtargeted agents are the most widely diffused PSMA-targeted radiopharmaceuticals. However, radiolabeling PSMA-targeted agents with 18 F may provide several advantages compared with 68 Ga radiolabeling for PET imaging, including a longer radiotracer half-life and a better PET images resolution [8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

“…e increased uptake of this radiopharmaceutical in PCa lesions compared with other PSMA-targeted tracers improves tumor-to-background ratios, facilitating the detection of small PCa lesions. Another clear advantage of 18 F-PSMA-1007 compared to other PSMA-targeted radiopharmaceuticals is its predominant excretion via the hepatobiliary rather than urinary system, allowing an excellent assessment of the pelvic region owing to the reduced interference of the urinary radioactivity [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Ferrari

Treglia

2021

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Background. Prostate-specific membrane antigen- (PSMA-) targeted agents labeled with fluorine-18 (18F) have recently become available to evaluate patients with biochemical recurrent prostate cancer (BRPCa) by using positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI). We performed a systematic review and meta-analysis about the detection rate (DR) of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa patients. Methods. A comprehensive computer literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases for studies published through 17 May 2021 was carried out using the following search algorithm: “PSMA” AND “1007”. Only studies providing data on the DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa were included. A random-effects model was used to calculate the pooled DR on a per scan basis. Results. Fifteen articles (853 patients) were selected and included in the systematic review, and ten were included in the quantitative analysis. Most of the studies reported a good DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa including also patients with low prostate-specific membrane antigen (PSA) values. The DR of 18F-PSMA-1007 PET/CT or PET/MRI was dependent on PSA serum values. The pooled DR was 81.3% (95% confidence interval: 74.6–88%) with statistical heterogeneity. A significant reporting bias (publication bias) was not detected. Conclusions. 18F-PSMA-1007 PET/CT or PET/MRI showed a good DR in BRPCa patients in line with other PSMA-targeted agents. The DR of 18F-PSMA-1007 PET/CT or PET/MRI is influenced by serum PSA values. These findings should be confirmed by prospective multicentric trials.

show abstract

Section: Introductionmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Ferrari

Treglia

2021

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“… 15 , 16 , 17 Actually, 18 F-PSMA-1007 has been recently introduced to clinical practice after successful preclinical studies. 37 , 38 , 39 To date, most of the recent studies on PCa detection and local staging with 18 F-PSMA-1007 were conducted using PET/CT, and the results 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 showed that 18 F-PSMA-1007 PET/CT were performed with sensitivities ranging from 71% to 100%, specificities ranging from 76% to 100%, and accuracies ranging from 80% to 100%. Although the overall diagnostic value was high, limited by the low resolution of soft tissue on CT, the false-negative and false-positive findings should still be taken into account in some studies, resulting in a relatively low diagnostic accuracy.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer

Zeng

Leng

Liao

et al. 2022

Prostate International

View full text Add to dashboard Cite

“…[ 18 F]-labeled radiotracers addressing PSMA have a great relevance today, with [ 18 F]-PSMA-1007 and [ 18 F]-DCFPyL recently evaluated also in RCC (Chen et al 2011 ; Foley et al 2020 ). Indeed, 18 F has cyclotron production and longer half-life in comparison to 68 Ga (110 vs. 68 min, respectively), and may therefore allow to ship the radiotracer to a greater number of Nuclear Medicine centers and to perform more daily exams (Foley et al 2020 ).…”

Section: Methodsmentioning

confidence: 99%

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives

Urso

Castello

Rocca

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Renal masses detection is continually increasing worldwide, with Renal Cell Carcinoma (RCC) accounting for approximately 90% of all renal cancers and remaining one of the most aggressive urological malignancies. Despite improvements in cancer management, accurate diagnosis and treatment strategy of RCC by computed tomography (CT) and magnetic resonance imaging (MRI) are still challenging. Prostate-Specific Membrane Antigen (PSMA) is known to be highly expressed on the endothelial cells of the neovasculature of several solid tumors other than prostate cancer, including RCC. In this context, recent preliminary studies reported a promising role for positron emission tomography (PET)/CT with radiolabeled molecules targeting PSMA, in alternative to fluorodeoxyglucose (FDG) in RCC patients. Purpose The aim of our review is to provide an updated overview of current evidences and major limitations regarding the use of PSMA PET/CT in RCC. Methods A literature search, up to 31 December 2021, was performed using the following electronic databases: PubMed, SCOPUS, Web of Science, and Google Scholar. Results The findings of this review suggest that PSMA PET/CT could represent a valid imaging option for diagnosis, staging, and therapy response evaluation in RCC, particularly in clear cell RCC. Conclusions Further studies are needed for this “relatively” new imaging modality to consolidate its indications, timing, and practical procedures.

show abstract

Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography–computed tomography: normal patterns, pearls, and pitfalls

Cited by 28 publications

References 62 publications

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives

Contact Info

Product

Resources

About